Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2026 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – –...
February 24, 2026 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359
February 23, 2026 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
February 23, 2026 07:00 ET | Source: Arvinas Inc.

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
February 17, 2026 07:00 ET | Source: Arvinas Inc.

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
February 12, 2026 07:00 ET | Source: Arvinas Inc.

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. ...
January 08, 2026 07:00 ET | Source: GlycoEra

GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline

GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline
December 06, 2025 08:05 ET | Source: Arvinas Inc.

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma...
November 26, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
November 24, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...